Information for Investors
UK & EU Investors
UK and EU investors should access further information via CrowdCube, the UK’s regulated equity crowdfunding platform.
US, Canada, Japan & China Investors
And other jurisdictions unable to invest through CrowdCube
Please contact Attomarker directly on:
info@attomarker.com
Risk Warning: Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment.
About Attomarker
Attomarker is a UK spin-out from the University of Exeter developing multiplex immunology diagnostics for infectious and post-viral conditions including Long COVID and Lyme. Proprietary, patented gold nanoparticle biophotonic sensors enable rapid, multi-biomarker analysis from a very small blood sample within 10 minutes.
Our beachhead commercial focus is Long Covid, where clinicians require tools to understand persistent symptoms, immune dysfunction, and recovery patterns. Our portfolio is designed to address these needs through rapid, accurate immune profiling, including with our UKCA-marked COVID Antibody Spectrum Test characterising Long Covid patients into clinically meaningful endotypes to target interventions and monitor recovery.
Attomarker’s technology is supported by peer-reviewed publications, variant-specific antibody research, and a development pathway enabling rapid expansion into adjacent diagnostic markets. It is protected by 8 granted patents.
Beachhead Market: Long Covid and Immune Status Diagnostics
Long Covid represents a significant global health challenge, and an enormous social burden, with sufferers lives and employment often devastated by seemingly intractable and debilitating symptoms. Published data indicates:
Up to 65 million people worldwide living with Long Covid or post-viral sequelae
Around 1.9 million people in the UK reporting long-term symptoms
Approximately 18 million adults in the US affected
Attomarker’s first commercial assays are designed specifically for this market.
Covid Antibody Spectrum Test
Our Covid Antibody Spectrum Test has a UKCA mark and is currently available through Attomarker’s laboratory, as well as on a research or compassionate use basis in other territories.
The test measures:
Antibody concentration and
Antibody quality (avidity)
across 15 SARS-CoV-2 variants, including multiple Omicron lineages, Delta, and ancestral strains.
Covid Antibody Spectrum Test allows classification of patients into immune endotypes:
Hypoimmune
Hyperimmune
Universal Response
which support clinical evaluation of ongoing symptoms, targeting treatments and recovery monitoring.
Companion Immune Diagnostics for Long Covid
Attomarker is developing a suite of additional immune function tests that complement our antibody spectrum test and expand diagnostic insight for Long Covid and similar post-viral conditions. These include:
Spike Protein Test
IgG Spectrum Test
Other immune function and immune status panels in development
Each test leverages the same underlying multiplex biochemical measurement platform, enabling efficient development and scalable deployment.
This portfolio forms a unified diagnostic ecosystem for Long Covid and post-viral syndromes.
Pipeline: Extension of Immune Diagnostics into Further Post-viral & Autoimmune Conditions
Attomarker has signed a co-development agreement with EpitogenX to leverage our technology platform and immune diagnostics expertise with Epitogen’s antigen discovery & development capability. This will enable the extension of our platform approach into:
Lyme Disease & Long Lyme
Hashimoto's Disease
Other immune and autoimmune conditions
According to Grand View Research, the global Lyme disease testing market is was valued at USD $10.85 billion in 2023, and is set to rise to USD $18.57 billion by 2030. It has the same under-served diagnostic characteristics as Long Covid.
Read more about the Attomarker and EpitogenX Strategic Co-Development Agreement. More information.
Hardware Roadmap: From Benchtop to Handheld
Current tests are developed for the Liscar 6 benchtop point-of-care device, which already holds a CE mark. This device supports high-precision multiplex measurement across multiple biomarkers.
To meet the growing demand for at-home and consumer diagnostics, Attomarker is also developing a handheld device capable of running multiplex assays outside clinical settings. This reflects a global shift toward decentralised, consumer-led health testing and positions the company for future expansion into the home diagnostics market.
Attomarker Liscar 6 Benchtop (CE-mark Approved)
Attomarker Handheld Device (in design for manufacture)
Regulatory Strategy
Attomarker’s regulatory pathway supports entry into the UK, US, and European markets, beginning with Long Covid.
United States
Attomarker will introduce its Covid Antibody Spectrum Test through CLIA-certified partner laboratories, enabling compliant deployment as a laboratory-developed test (LDT). Real-world evidence gathered during laboratory use will inform whether a future FDA submission is required for broader commercialisation.
United Kingdom
- Covid Antibody Spectrum Test carries a UKCA mark for use in UK.
- The Liscar 6 analyser holds a CE mark.
Europe
Attomarker plans to pursue a full CE mark for its Covid Antibody Spectrum Test, enabling wider European adoption under the IVDR framework.
This phased approach allows early commercialisation while building the regulatory foundation for wider diagnostic expansion.
Commercial Progress
- Covid Antibody Spectrum Test operational in the UK through Attomarker’s laboratory
- Clinical and patient demand from Long Covid communities from Hong Kong to Seattle
- Peer-reviewed publications on antibody kinetics, variant-specific immunity, and immune endotype analysis
- Pipeline assays under development for immune status, Spike protein detection, and IgG spectrum profiling
- Multiplex technology platform architected for scalable assay development
- Hardware roadmap positioned for both clinical and consumer markets
CrowdCube Fundraising Campaign
Attomarker is engaged in an Acceleration Round with access through Crowdcube UK, EU and certain other RoW jurisdictions. To register and review the full pitch, risk information, and investment documents please visit the CrowdCube FCA-authorised platform.
US, Canada, Japan, China and certain other jurisdictions need to contact Attomarker directly on info@attomarker.com
Investment Updates
You may register for investor and investment updates by completing the short form below. We will only use your details for this express purpose.
Register for Updates
Compliance Notice
This page provides general information only and is not an investment promotion.
Investing in early-stage companies carries significant risk, including loss of capital, illiquidity, and dilution. Independent financial advice should be sought.